Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Shingrix safe in post-transplant patients

Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2

Key clinical point: The adjuvanted herpes zoster vaccine met its efficacy endpoint in myeloma patients after transplant.

Major finding: Efficacy was 68.17% for preventing herpes zoster among HSCT recipients.

Study details: A randomized, observer blind, placebo-controlled phase 3 study of 1,846 post-HSCT recipients.

Disclosures: The study was sponsored by GlaxoSmithKline. Dr. de la Serna reported relationships with multiple pharmaceutical companies.

Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2.

Read the full article.


Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2

This Week's Must Reads

Consider bleeding disorders in heavy menstrual bleeding, O’Brien B et al. J Pediatr Adolesc Gynecol. 2018 Nov 22 . doi: 10.1016/j.jpag.2018.11.005

Lower-dose treatment could save money in aTTP, Zwicker JI et al. ASH 2018, Abstract 374

Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5

Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491

Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1

Must Reads in Cellular Therapy

HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489